# Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

> **NCT06093425** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Suzhou Transcenta Therapeutics Co., Ltd.** · enrollment: 820 (estimated)

## Conditions studied

- Gastric Cancer
- Gastroesophageal-junction Cancer
- Advanced Cancer

## Interventions

- **DRUG:** Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil
- **DRUG:** Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil

## Key facts

- **NCT ID:** NCT06093425
- **Lead sponsor:** Suzhou Transcenta Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2029-10-01
- **Final completion:** 2030-01-31
- **Target enrollment:** 820 (ESTIMATED)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06093425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06093425, "Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06093425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*